NOS3 and Hypercholesterolemia: There are different mechanisms that lead to reduced eNOS activity and result in a decrease in NO bioavailability; some of these are the modification (OGlcNAcylation) of eNOS, activation of PKC, impairment of signaling pathways related to soluble guanylate cyclase due to hypercholesterolemia, and the interaction of AGEs and their soluble receptor [35].